Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-IPF: Bexotegrast in Idiopathic Pulmonary Fibrosis
CTR20243948Phase 3Terminated
- Sponsor
- Pliant Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bexotegrast in idiopathic pulmonary fibrosis (IPF), sponsored by Pliant Therapeutics. Started Oct 2024; status: terminated.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20243948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243948.